Director Invus Global bought 1,538,462 shares (1.54M) of LXRX at $1.30 for $2,000,000.60 on 2026-02-02
Invus Global Management, LLC purchased 1,538,462 shares for $2,000,000.60 at $1.30 per share, a substantial discretionary acquisition by a director of Lexicon Pharmaceuticals. The transaction is notable given the company's operating profile: Lexicon generated $14,182,000.00 in latest quarterly revenue but reported a net loss of $-12,769,000.00 in the same period, and was unprofitable over its most recent full fiscal year. The stock currently trades at $1.27, slightly below the $1.30 purchase price. The 52-week range of $0.29–$1.76 places the transaction near the upper portion of recent historical trading, though the stock is -27.8% from its 52-week high. Investors should evaluate whether this director-level commitment reflects confidence in Lexicon's strategic direction or product pipeline, balanced against the sustained operating losses and modest revenue base.